Latest news with #SteveChristo
Forbes
a day ago
- Forbes
When To See Sydney Harbor's First Total Solar Eclipse Since 1857
The sun sets behind the Sydney Harbour Bridge and the Sydney Opera House before the lights come on ... More for Vivid Sydney 2024 on May 28, 2024 in Sydney, Australia .(Photo by Steve Christo - Corbis/Corbis via Getty Images) There's a trio of incredible total solar eclipses coming, with as much as 13 minutes of totality possible within less than two years in some of the world's most attractive locations. On Aug. 12, 2026, Greenland, Iceland and northern Spain see totality. It happens again on Aug. 2, 2027, in southern Spain and across North Africa, including temple-filled Luxor in Egypt. Given that booking early is essential since North America woke up to total solar eclipses in 2017 and 2024, most eclipse chasers will have made detailed plans for both of those events by now, but few will have thought much about the eclipse that ends the spectacular run — a long totality on July 22, 2028, in Australia and New Zealand. The Astronomical Society of Australia has recently published a website about the 2028 eclipse, which includes a countdown timer and advice on safely watching the eclipse. Here's what you need to know. Extreme tidal range shown here at low tide as found on Bigge Island, Kimberley, Western Australia, ... More Australia, Pacific Eclipse 2028 Will Cross Two Countries, Four Landmasses On Saturday, July 22, 2028, a path of totality 143 miles (230 kilometers) wide will cross Christmas Island and the Cocos (Keeling) Islands (both territories of Australia), Australia and New Zealand. In Australia, the path crosses from northwest to southeast, entering at Bigge Island on the Kimberly coast in Western Australia and exiting at Sydney in New South Wales. Eclipse 2028 Will Plunge Iconic Landmarks Into Totality Totality will be visible across Sydney and its suburbs — its first total solar eclipse since 1857 and last until 2858. Sydney Opera House and Harbour Bridge will both go dark, providing iconic silhouettes during totality, as will Anzac Bridge, Darling Harbour and the Bondi to Coogee coast. It's a rare chance for eclipse photographers to capture urban eclipse imagery. Other landmarks on the path include the Bungle Bungle Range in Purnululu National Park, Western Australia, Karlu Karlu (Devils Marbles) in the Northern Territory, and Siding Springs Observatory in Warrumbungle, New South Wales. The path of the total solar eclipse on July 22, 2028. Eclipse 2028's Totality Will Be Longest In Western Australia The mathematical point of maximum eclipse is 5 minutes 10 seconds totality in a very remote area of Western Australia. However, the closest accessible areas — islands to the west off the Kimberly coast and the region to the east close to Lake Argyle — both offer 5 minutes and 3-4 seconds, which is the maximum that can practically be experienced thanks to the bumpy profile of the moon's shadow. Clear Skies Are More Likely Away From Sydney For Eclipse 2028 It may be an iconic destination and where most people experience this eclipse (almost all of the 6.3 million people in the path live in Sydney), but the chances of a clear sky in Sydney during mid-winter are a lot smaller than in remote Outback regions. According to Christmas Island has a 65% chance of cloud, Cocos Islands 57% and Sydney 47%. Meanwhile, the Kimberly Coast and Western Australia are 7%, and the Northern Territory is around 20%. The chance of cloud gradually increases as the path approaches Sydney. City of Dunedin at Dusk - sunset. High angle view. Eclipse 2028 Will End Dramatically In New Zealand The eclipse path also crosses New Zealand's South Island, where there's around a 60-70% chance of cloud. It will be the country's first total solar eclipse since 1965. Remarkably, the centerline of the path — where totality lasts just shy of three minutes — passes over tourist mecca Queenstown and Dunedin. However, from New Zealand, the eclipse will happen just 11 degrees above the northwestern horizon, making sightlines difficult. Observing locations will need to be checked out in advance very carefully to avoid missing the magical moments. New Zealand will also have a fabulous "ring of fire" annular solar eclipse on Mar. 9, 2035, followed by another total solar eclipse on Jul. 13, 2037. Wishing you clear skies and wide eyes.
RNZ News
4 days ago
- Sport
- RNZ News
Football live updates: Wellington Phoenix v Wrexham AFC
Wrexham winger Ryan Longman. Photo: Steve Christo - Corbis The Wrexham roadshow has rolled into the capital, where a big crowd will watch their 'Nix take on football's modern-day Cinderella story. Kickoff is at 5pm NZT.
Newsweek
15-07-2025
- Health
- Newsweek
Men Are Gaining More Confidence From Ozempic Than Women: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some may associate Ozempic and other GLP-1 medications with women trying to lose weight, it turns out that men are the ones gaining the most significant confidence boosts from it. In a Kinsey Institute and survey of GLP-1 users, men were three times more likely than women to say GLP-1s gave them more confidence. They also experienced more notable improvements in their dating lives and libidos. Why It Matters In recent years, the use of weight-loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists has surged. Popular products include Ozempic, Mounjaro, Wegovy and Zephound and have been a game changer for many Americans who are obese or have type 2 diabetes. For patients who successfully lose weight, there can be significant changes in their mental health as well as their personal dating lives, but this impact appears to be more pronounced among male users. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Steve Christo - Corbis/Corbis via Getty Images What To Know Across the entire survey sample, drugs like Ozempic were having major effects on users' dating lives. While 59 percent of users said the drugs changed their dating experiences, men experienced a more notable impact on their confidence levels and sex lives, according to the report. Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and increased sexual activity. Still, there were some negative implications for men, of which 60 percent said they feared being judged for using GLP-1s and worried they'd be seen as "less masculine" for doing so. Of all GLP-1 users surveyed, 12 percent said they were going on more dates, and 14 percent said they were getting more matches on dating apps. Meanwhile, a whopping 52 percent reported changes in their sex lives. What People Are Saying Dr. Justin Lehmiller, the Kinsey Institute study lead, said in a statement: "I think there's a very nuanced story to tell here. How these drugs impact your sex life will depend on a variety of factors, including drug dosage and drug type, speed of weight loss, starting and ending weight, and how much you changed your health and fitness habits at the same time." "Sexually speaking, it appears that men are experiencing more positive and more negative impacts of GLP-1 medications." What Happens Next The long-term implications of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. GLP-1 medications are also associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea, and even stomach paralysis in rare cases.
Extra.ie
04-07-2025
- Sport
- Extra.ie
Hurls out as the Lions prepare for stellar 'Tahs test
The British and Irish Lions' tour down under rumbles on this Saturday as they go down to Sydney to face the New South Wales Waratahs. Andy Farrell has yet again made numerous changes to his starting team, though there's no spot for his son Owen after he was called into the squad to replace the injured Elliot Daly. Tadhg Beirne is named as captain of the side in place of Maro Itoje to become the second Irish captain of this tour after Dan Sheehan's spell as skipper against the Western Force. Tadhg Beirne during a British & Irish Lions captain's run at North Sydney Oval in Sydney Pic:Steve Christo/Sportsfile Beirne also becomes the seventh Munster man to captain the Lions after Tom Kiernan, Ronan O'Gara, Paul O'Connell, Donncha O'Callaghan, Peter O'Mahony and Conor Murray. There was definitely a Munster feel to the captains' run as Jack Conan popped up with a hurl and was caught hitting a few shots with Englishman Ben Earl. Jack Conan plays hurling after a British & Irish Lions captain's run Pic: Steve Christo/Sportsfile Wicklow man Jack Conan has spoken a few times about his love for GAA recently. In the run up to Leinster's URC final against the Bulls Conan spoke about his memories of Wicklow winning the Tommy Murphy Cup at Croke Park back in 2007. He would subsequently be the man that lifted the URC trophy at GAA HQ after Leinster were resounding winners against their South African rivals. Conan showed Ben Earls, who's starting in place of him this Saturday, a few tricks and got the England and Saracens star to hit a few sliotars across the pitch during the captain's run. Ben Earl during a British & Irish Lions captain's run Pic:Steve Christo/Sportsfile Earl will be joined by Josh van der Flier and Henry Pollock in the back row as Andy Farrell has named another six Irish players in this Saturday's starting team. Van der Flier will be joined by Finlay Bealham, Beirne, James Ryan, Mack Hansen and Hugo Keenan who is looking to finally make his Lions debut after he was a late withdrawal from Wednesday's game against the Reds due to illness. Keenan along with Scots Ben White and Blair Kinghorn are all set to make their Lions debut. Both Scots joined the camp late, White as a replacement for the injured Tomos Williams and Kinghorn made his way down under after playing a starring role as Toulouse won the Top 14 final after an extra-time win over Bordeaux-Begles. Dan Sheehan along with Tadhg Furlong are on the bench as Andy Farrell goes for a 6/2 split with White and Marcus Smith covering the backline on the bench. The Waratahs will offer a stern challenge to the Lions in the form of their star man, the 'Tongan Thor' Taniela Tupou. Tupou is one of the strongest players on the planet and when fit, is impossible to stop. He is joined by Wallaby winger Andrew Kellaway who has been released from the Wallabies squad to play in this match. A former Northampton Saint, Kellaway is a stellar winger who offers huge amount of pace. You can catch the game live on Sky Sports Main Event and Sky Sports Action at 11am on Saturday.
Newsweek
25-06-2025
- Health
- Newsweek
Ozempic Linked to Significant Reduction in Dementia—Study
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients with type 2 diabetes, a recent study reported. A new study published in the Journal of Alzheimer's Disease analyzed the medical records of over 1.7 million U.S. adults and found that semaglutide users experienced a notably lower risk of dementia compared to patients treated with insulin, metformin, or older GLP-1 agonists. These findings, publicly released on Tuesday, come as researchers and clinicians continue to search for effective means to mitigate the growing dementia epidemic in the U.S. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Photo by Steve Christo - Corbis/Corbis via Getty Images Why It Matters With over 6 million Americans diagnosed with dementia and more than 100,000 related deaths each year, the potential for semaglutide to meaningfully lower risk could have sweeping public health implications. Dementia does not have a cure, and nearly half of all cases are thought to be preventable by addressing risk factors like obesity, type 2 diabetes, and cardiovascular disease, the New York Post reported. Evidence supporting semaglutide's neuroprotective effects may inform future prevention strategies among high-risk populations in the U.S. What To Know Landmark Study Shows Sharp Risk Reduction Researchers at Case Western Reserve School of Medicine, National Institutes of Health and the MetroHealth System in Cleveland examined the health records of 1,710,995 U.S. patients with type 2 diabetes who had no prior diagnosis of Alzheimer's disease-related dementia (ADRD). The study used a statistical method simulating a randomized clinical trial, comparing dementia diagnoses among those prescribed semaglutide, insulin, metformin, and older GLP-1 receptor agonists. Patients treated with semaglutide had a 46 percent lower risk of developing ADRD than those receiving insulin, a 33 percent lower risk than those on metformin, and a 20 percent lower risk than those on earlier GLP-1 agonists. The effect was particularly pronounced for vascular dementia, one of the most common subtypes. No protective association was found for frontotemporal dementia or Lewy body dementia. Wide Demographic Impact Observed The protective association was consistent among subgroups, including younger and older patients, men and women, and those with and without obesity. Researchers found the risk reduction was especially evident among older adults and women. What is Semaglutide? Semaglutide is a glucagon-like peptide-1 receptor agonist that helps regulate blood sugar, lowers body weight, and offers cardiovascular benefits for patients with diabetes. The drug can help improve insulin sensitivity, protect blood vessels, and reduce inflammation in the brain. Important Study Limitations Authors acknowledged limitations, including reliance on administrative diagnosis codes, which are subject to underdiagnosis and misclassification, data on medication adherence, cognitive test scores, and genetic risk factors were unavailable. Variations in clinical practice and health care use variations could also affect findings. Researchers emphasized the need for preclinical and clinical studies to establish causal effects. Additional International Data A separate study by Oxford University, published in Lancet's eClinicalMedicine journal, analyzed more than 100 million U.S. medical records and found that Ozempic users experienced lower rates of cognitive decline and nicotine use compared to those on other diabetes medications. This study also did not find a higher risk of anxiety, depression, or other neurological and psychiatric conditions with Ozempic. The researchers emphasized that the results were limited to diabetic patients and require more rigorous randomized controlled trials. What People Are Saying The researchers of the study, in a news article published by the American Journal of Managed Care: "In a real-world population with T2D [type 2 diabetes] who had no prior diagnosis of AD/ADRD [Alzheimer disease/Alzheimer disease-related dementia], our study shows that semaglutide was associated with a significantly lower risk of overall ADRD incidence compared with other antidiabetic medications, including insulin, metformin, and other GLP-1RAs. Significant reductions were observed in older and younger patients, women and men, and patients with and without obesity." Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, in comments to Reuters: "The answer to all those limitations is to do a randomized clinical trial, which is exactly what Novo is doing." What Happens Next Novo Nordisk, the maker of Ozempic, began testing semaglutide in patients with early Alzheimer's disease in 2021. The results are expected sometime this year. Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@
